- Home
- REPL vs DNTH Comparison
REPL vs DNTH Comparison
Compare REPL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- DNTH
- Stock Information
- Founded
- REPL 2015
- DNTH 2015
- Country
- REPL United States
- DNTH United States
- Employees
- REPL N/A
- DNTH N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- REPL Health Care
- DNTH Health Care
- Exchange
- REPL Nasdaq
- DNTH Nasdaq
- Market Cap
- REPL 816.4M
- DNTH 823.1M
- IPO Year
- REPL 2018
- DNTH N/A
- Fundamental
- Price
- REPL $11.05
- DNTH $20.27
- Analyst Decision
- REPL Strong Buy
- DNTH Strong Buy
- Analyst Count
- REPL 4
- DNTH 8
- Target Price
- REPL $17.00
- DNTH $46.43
- AVG Volume (30 Days)
- REPL 488.6K
- DNTH 291.2K
- Earning Date
- REPL 11-12-2024
- DNTH 11-07-2024
- Dividend Yield
- REPL N/A
- DNTH N/A
- EPS Growth
- REPL N/A
- DNTH N/A
- EPS
- REPL N/A
- DNTH N/A
- Revenue
- REPL N/A
- DNTH $5,366,000.00
- Revenue This Year
- REPL N/A
- DNTH $44.94
- Revenue Next Year
- REPL $469.74
- DNTH N/A
- P/E Ratio
- REPL N/A
- DNTH N/A
- Revenue Growth
- REPL N/A
- DNTH 51.41
- 52 Week Low
- REPL $4.92
- DNTH $6.58
- 52 Week High
- REPL $12.97
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- REPL 43.04
- DNTH 22.81
- Support Level
- REPL $10.57
- DNTH $22.19
- Resistance Level
- REPL $12.73
- DNTH $28.56
- Average True Range (ATR)
- REPL 0.67
- DNTH 2.02
- MACD
- REPL -0.16
- DNTH -0.88
- Stochastic Oscillator
- REPL 20.00
- DNTH 3.38
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.